- Home
- LCFY vs KZIA Comparison
LCFY vs KZIA Comparison
Compare LCFY & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCFY
- KZIA
- Stock Information
- Founded
- LCFY 2009
- KZIA 1994
- Country
- LCFY Australia
- KZIA Australia
- Employees
- LCFY N/A
- KZIA N/A
- Industry
- LCFY
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- LCFY
- KZIA Health Care
- Exchange
- LCFY Nasdaq
- KZIA Nasdaq
- Market Cap
- LCFY 9.2M
- KZIA 9.6M
- IPO Year
- LCFY 2022
- KZIA 1999
- Fundamental
- Price
- LCFY $3.20
- KZIA $8.60
- Analyst Decision
- LCFY
- KZIA Strong Buy
- Analyst Count
- LCFY 0
- KZIA 3
- Target Price
- LCFY N/A
- KZIA $16.00
- AVG Volume (30 Days)
- LCFY 18.8K
- KZIA 1.8M
- Earning Date
- LCFY 11-12-2025
- KZIA 12-26-2025
- Dividend Yield
- LCFY N/A
- KZIA N/A
- EPS Growth
- LCFY N/A
- KZIA N/A
- EPS
- LCFY N/A
- KZIA N/A
- Revenue
- LCFY $2,099,713.00
- KZIA $1,199,108.00
- Revenue This Year
- LCFY N/A
- KZIA N/A
- Revenue Next Year
- LCFY N/A
- KZIA N/A
- P/E Ratio
- LCFY N/A
- KZIA N/A
- Revenue Growth
- LCFY N/A
- KZIA N/A
- 52 Week Low
- LCFY $2.51
- KZIA $2.86
- 52 Week High
- LCFY $13.98
- KZIA $29.30
- Technical
- Relative Strength Index (RSI)
- LCFY 21.46
- KZIA 61.89
- Support Level
- LCFY $3.14
- KZIA $7.09
- Resistance Level
- LCFY $3.80
- KZIA $8.75
- Average True Range (ATR)
- LCFY 0.26
- KZIA 0.64
- MACD
- LCFY -0.02
- KZIA 0.14
- Stochastic Oscillator
- LCFY 7.69
- KZIA 94.33
About LCFY Locafy Limited
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.